−1.57USD
−100.16 MUSD
62.97 M
About Edgewise Therapeutics, Inc.
Sector
Industry
CEO
Kevin Koch
Website
Headquarters
Boulder
Employees (FY)
88
Founded
2017
ISIN
US28036F1057
FIGI
BBG00K4Y2H24
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of EWTX is 15.10 USD — it has decreased by 2.27% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Edgewise Therapeutics, Inc. stocks are traded under the ticker EWTX.
Edgewise Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
EWTX stock is 5.77% volatile and has beta coefficient of 1.09. Check out the list of the most volatile stocks — is Edgewise Therapeutics, Inc. there?
One year price forecast for Edgewise Therapeutics, Inc. has a max estimate of 48.00 USD and a min estimate of 25.00 USD.
EWTX earnings for the last quarter are −0.41 USD per share, whereas the estimation was −0.40 USD resulting in a −3.54% surprise. The estimated earnings for the next quarter are −0.43 USD per share. See more details about Edgewise Therapeutics, Inc. earnings.
Yes, you can track Edgewise Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
EWTX stock has fallen by 7.36% compared to the previous week, the month change is a 5.21% fall, over the last year Edgewise Therapeutics, Inc. has showed a 131.24% increase.
EWTX net income for the last quarter is −30.14 M USD, while the quarter before that showed −25.71 M USD of net income which accounts for −17.23% change. Track more Edgewise Therapeutics, Inc. financial stats to get the full picture.
Today Edgewise Therapeutics, Inc. has the market capitalization of 1.44 B, it has decreased by 4.47% over the last week.
No, EWTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, EWTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Edgewise Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 88.00 employees. See our rating of the largest employees — is Edgewise Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Edgewise Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Edgewise Therapeutics, Inc. stock shows the buy signal. See more of Edgewise Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Edgewise Therapeutics, Inc. future price: according to them, EWTX price has a max estimate of 48.00 USD and a min estimate of 25.00 USD. Read a more detailed Edgewise Therapeutics, Inc. forecast: see what analysts think of Edgewise Therapeutics, Inc. and suggest that you do with its stocks.